List of Therapeutic Companies in Netherlands - 80

2-BBB is developing medicines for the treatment of devastating brain diseases. Our proprietary liposomal G-Technology® facilitates entry to the brain while simultaneously enabling sustained delivery of systemically administered therapeutics. Our technology has been shown to be compatible with approved as well as novel therapeutic entities. We have two clinical programs, one targeting multiple indications of brain cancers and the other neuro-inflammatory diseases.

Ace has been delivering custom pharmaceutical solutions for specific patient needs for over 30 years. With our own registrations, compounded products and cosmetics we provide a solution for pharmacists all over the world. In addition we make clinical trial medication on behalf of our customer.

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases.

Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

Alveron Pharma is developing a unique coagulation platform technology with the world's first cyclodextrin-based anticoagulant reversal drug

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of both rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVero™) that, for the first time, makes it possible to produce SV40-derived vectors suitable for therapeutic use. Combining SuperVero™ with its genetically engineered SVec viral vector, the company’s fully-integrated gene therapy platform is truly unique in its intrinsic capability to deliver transgenes without eliciting immune responses to the vector nor to the transgene product. Leveraging this ‘natural’ non-immunogenicity feature of its gene delivery system in humans, Amarna is developing a broad pipeline of safe, effective and durable gene therapies focused on genetic disorders, autoimmune diseases and chronic inflammation. Founded in 2008, Amarna’s head office is based in Leiden Bio Science Park, the Netherlands, with a research subsidiary located in Seville, Spain.

AM-Pharma BV is a biopharmaceutical company developing recombinant Alkaline Phosphatase for clinical use.

AM–Pharma is a biopharmaceutical company developing proprietary recombinant human Alkaline Phosphatase (AP) therapeutics, which have the potential to transform the treatment prospects for patients with Acute Kidney Injury, Inflammatory Bowel Disease and Hypophosphatasia.

Amphera is a late-stage biotechnology company developing cell therapies to treat cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.

ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies and financial support from the Dutch government. The collaboration between the clinical, biomechanical and polymer experts has been instrumental in the development of our Meniscus Prosthesis. Artimis® will be the first anatomically shaped polymer based meniscus implant. Please note, Artimis® is an investigational device in development and is not available for clinical use the coming years. More information can be found on www.atromedical.com

Audion Therapeutics is a private biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of acquired hearing loss. Audion’s headquarters are in Amsterdam, The Netherlands with a presence in the Boston area. Founders are Professor Albert Edge of the MEEI (Harvard Medical School) in Boston, Dr Helmuth van Es, founder of Galapagos, Citryll, Antabio and Effecta Pharma and Rolf Jan Rutten CEO. Investors are Eli Lilly and Inkef Capital and the early clinical development of its lead compound LY3056480 was also funded by a Horizon2020 grant from the EU for a consortium of ENT clinical sites in UK, Germany and Greece.

At Avidicure, we invent and develop entirely new antibody therapies, called "AVC-Boosters". Our first-in-class product platform is designed to deliver targeted and potent immune-modulating treatments for patients with cancer or auto-immune diseases.

Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees.

BIMINI Biotech BV is an innovative biotech start-up that is developing unique compounds for oncology.

BiOraliX' proprietary formulation technology provides a new way to orally deliver biopharmaceutical therapies patient friendly and with superior bioavailability. For patients, self-medication is now within reach for the most complex biologics treatments, especially for chronic diseases such as rheumatoid arthritis, allergy and asthma.

With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.

Catapult Therapeutics is a privately held Dutch biotech company developing CAP-100 – an innovative first-in-class humanized anti-CCR7 antibody.

Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers' needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek', our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.

Cimaas - Our mission is achieving a better cure for cancer. For this, CiMaas develops therapies engaging the immune system for the treatment of a steadily growing population facing cancer that cannot be cured by the current standard of care. A better cure relates to safe technology taking away several of the severe side-effects of current therapies.

CimCure’s solution is a vaccination based immunotherapy directed to the tumor blood vessels that are common to most solid tumors.

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

Complement Pharma is a biotech company developing new therapeutics that target the complement system, an important component of the immune system. With a focus on C6 we aim to fight neurodegeneration in indications like TBI, ALS and MS. Our promising pre-clinical data, shows safety and efficacy of C6 inhibition to modify disease progression in the mentioned indications and beyond. Our first antibody, with excellent characteristics is now getting ready for GMP production and clinical trials. In June 2018 Alexion and Complement Pharma announced their collaboration to develop C6 complement inhibitor CP010 for neurodegenerative disorders.

Cortalix is a clinical-stage biopharmaceutical company developing imaging diagnostics and targeted radiotherapeutics based on its proprietary single domain antibodies (nanobodies) platform. Cortalix developed a pipeline of radiopharmaceuticals that target fibrogenesis-related membrane receptors and proteins that appear in early stage fibrotic diseases such as in pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis and several solid cancers with fibrotic stroma, including colon cancer and pancreatic cancer. The Cortalix technology platform is based on the screening and selection of single domain antibodies for myofibroblast-specific membrane proteins and receptors including PDGFRA (CD140a), PDGFRB (CD140b), EGFR, IGF-2R (CD222) and FAP. Our nanobodies do contain a functional group that can chelate a radionuclide suitable for nuclear imaging. Eventually the platform allows for a theranostic approach in cancer using the same single domain antibody for patient identification, targeted therapy and disease monitoring (a combined diagnostic and therapeutic in 1 molecule). Cortalix wants to share its single domain antibodies platform, the selection of new candidate molecules from it and, if appropriate, the development of new radiopharmaceuticals with others and offers this knowledge as a service, whether or not under license.

Aberrant functioning of kinases is known to be an important driver in cancer. Targeting hereof has proven to be extremely successful and has already revolutionized the management of numerous types of cancer. At Crossfire Oncology we approach kinases from three different angles: inhibitors, degraders, and degrader antibody conjugates. This tailored approach allows us to design kinase targeting drugs that aim to maximize the therapeutic benefit for cancer patients.

CyTuVax develops therapeutic vaccines against cancer and protective vaccines against viral & bacterial pathogens for which there is a high medical need. The patient is at the core in our vaccine development in which we apply our powerful adjuvant platform technology.

DegenRx is a biotech company developing AAV-mediated gene therapy for the treatment of Alzheimer’s disease. Using Adeno-Associated-Viral (AAV) vectors we deliver genes in the brain that initiate the local production of therapeutic antibodies

Fagron is committed to the personalization of health treatment to cover the individual patient's need through Pharmaceutical Compounding & Sterile Outsourcing Services. Pharmaceutical Compounding allows pharmacists and prescribers to create medication that satisfies patients' needs. Through our services towards personalization, we can extend the range of mass-produced medication and keep available medicaments that are no longer offered commercially in an affordable way for those who need them. Fagron was founded in the Netherlands in 1990 and is currently present in 35 countries worldwide enabling pharmacists, prescribers, hospitals, and industry to provide quality, safety, and service for their patients. Together we create the future of personalizing medicine.

Flindr Therapeutics B.V. is a precision oncology therapeutics company that is developing first-in-class small molecule inhibitors. The company has secured €20 million in Series A financing to advance its pipeline of precision oncology treatments.

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

HAL Allergy is one of the European top players in the development, production and distribution of allergen immunotherapies for the treatment and prevention of allergic diseases. With all our activities the patient’s well-being is always our top priority. At our headquarters in the Leiden Bio Science Park (NL) we focus on the development and manufacturing of modified allergen extracts for the therapeutic and diagnostic purposes of respiratory and food allergies. At HAL Allergy, we foster open discussions, an entrepreneurial spirit and close collaborations within the teams and with our international colleagues. The HAL Allergy team sums up more than 300 highly specialized people across various functions. If you too would like to become part of an innovative and challenging pharmaceutical manufacturer, then this is a perfect opportunity! Join HAL Allergy & drive innovation!

Hercules Pharmaceuticals, Inc is a fully independent pharmaceutical wholesale distributor accredited and licensed by the National Association of Boards of Pharmacy (NABP) in all 50 states. They serve the full spectrum of pharmaceutical care, including retail, compounding, and specialty pharmacy. Hercules Pharmaceuticals is committed to providing high-quality pharmaceuticals and exceptional customer service to their clients.

HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoids. HUB´s Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides services its organoid biobank.

Hybridize Therapeutics is a spin-off from the Leiden University Medical Center and is a therapeutic company focused on developing kidney-protecting modalities for untreated kidney diseases.

InnoCore specializes in the formulation, process development, and manufacturing of long acting and minimally invasive injectable drug delivery products. InnoCore offers a unique and highly tunable polymer platform to control the delivery drug compounds, including small molecules (e.g. peptides and low solubles) and biologics (e.g. proteins and antibodies). Our proprietary polymer platform features a variety of benefits to your API's such as: - solving toxicity challenges - maintaining/increasing stability and structural integrity of sensitive compounds (e.g. by applying low temperature process conditions during manufacturing) - sustained release of of drug molecules from days up to at least 6 months - precise control over particle size (preventing absorption by macrophages and ensuring injectability) - ensuring smooth bioavailability - enabling the use of small needle sizes for patient compliance By merging developmental collaborations and licensing partnerships with our exclusive SynBiosys biodegradable polymer technologies, we generate innovative injectable and implantable drug delivery products. We invite you to navigate through our website and discover how we can enhance the performance of your device and/or drug and add value to your product pipeline.

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. SLP®immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP®lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo®), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was recently approved by the FDA as monotherapy for patients with advanced cutaneous squamous cell carcinoma. ISA develops a diverse SLP®immunotherapy portfolio targeting unmet medical needs in cancer and chronic infections, including tailored therapy for rare diseases. ISA´s most advanced clinical-stage immunotherapeutic is ISA101, an SLP® immunotherapy targeting human papillomavirus (HPV)-induced diseases. It is currently in clinical development in advanced and recurrent cervical cancer, incurable HPV16-postive solid tumors and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV. The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com SLP® and AMPLIVANT® are registered trademarks in Europe.

We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases

Kling Biotherapeutics is a clinical-stage, privately held biotech company focused on discovery and development of antibody based therapeutics. The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells. Kling-Select relies on a fully-owned and well-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralising antibodies for various infectious diseases such as RSV (Nirsevimab/Beyfortus), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor-infiltrating B cells derived from cancer patients and produced a portfolio of novel and selective target-antibody pairs. The unbiased nature of this discovery platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches. Kling-Evolve enables the in vitro maturation of B cell clones against targets of interest. This powerful technology can be used for the rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets. In addition to platform technologies, Kling Biotherapeutics is pursuing asset pipeline programs with KBA1412 currently in phase I, and multiple programs in preclinical development.

Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Lead Pharma is a clinical-stage pharmaceutical research and development company located in Oss, Netherlands. A spinoff from the Hubrecht Institute and the University Medical Center Utrecht, it focuses on discovering and developing innovative small-molecule therapies for autoimmune diseases and cancer. The company operates from Pivot Park, a biopharmaceutical life sciences campus, equipped with labs for all stages of drug discovery, including medicinal chemistry and pharmacology. The management team includes CEO Frans van den Berg and Chief Scientific Officer Arthur Oubrie, supported by a skilled workforce of 29 employees, many of whom have advanced degrees. Lead Pharma is committed to innovation, with a pipeline of oral therapies designed for efficacy and safety. The company actively pursues partnerships, including a collaboration with Roche to develop treatments for immune-mediated diseases. Lead Pharma has raised $11.86 million in funding and holds 10 patents, emphasizing its focus on advancing science in the pharmaceutical sector.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Mair Therapeutics is a preclinical-stage drug discovery company focused on the discovery and development of a small-molecule ion channel activator to treat Parkinson's disease.

Matisse Pharmaceuticals BV was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development program is the development of a medicine to fight sepsis and septic shock, which is currently in clinical phase.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

Modra (Modulated Oral Drug Absorption) Pharmaceuticals B.V. is a spin-out from two internationally acclaimed centers of excellence in oncology, the ‘Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)’ and the MC Slotervaart (Slotervaart) in Amsterdam. Modra Pharmaceuticals is a clinical stage company that develops new treatment paradigms by enabling oral bioavailability of existing anticancer drugs, “the iv to oral switch”, to improve cancer therapy and supportive care. Modra Pharmaceuticals has several products in preclinical and clinical development including oral formulations of docetaxel and paclitaxel.

The Netherlands Center for the Clinical advancement of Cell and Gene Therapies (NecstGen), situated in Leiden, comprises of a state-of-the-art facility and expert knowledge for the development, production, and commercialization of Cell and Gene Therapies. NecstGen helps academic and industrial Cell & Gene Therapy developers to enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC and regulatory affairs in a brand new 4,000 m2 development & GMP manufacturing facility. We enable the next generation of therapies by translating research programs into actionalbe health solutions for patients. Our service offering: A flexible Cell and Gene Therapy manufacturing model - Full contract manufacturing services by our expert team for Cell Therapy and Viral Vector - We manufacture Pre-clinical or toxicology study material, Phase I, Phase II clinical trial material - GMP rental for any mammalian cell-based therapy type, including Cell and Viral Vector based therapies - QC, QA, and QP services supporting our cleanroom rental - Hybrid support on a flexible basis where our team compliments yours Process and assay development for Cell Therapies and Viral Vector - Process design and optimisation - Scale-up to clinically relevant volumes - Automation and closed processes - Assay development for in-process controls, release- and potency tests - Technology transfer in and out with flexibility in-mind for the future progress of your manufacturing - Consultancy-based work to advise on decision making Talk to NecstGen today about your needs for: - Induced Pluripotent Stem Cells (iPSC) - Chimeric Antigen Receptor T-Cells (CAR-T), Tumor Infiltrating Lymphocytes (TIL) T-Cell Receptor Modified T-Cells (TCR-T) - Natural Killer (NK) Cells/CAR-NK Cells - Dendritic Cells (DC) - Mesenchymal Stromal Cells (MSC) - Lentivirus (LV) - Aden-associated virus (AAV) - Oncolytic viruses - Cleanroom rental for any mammalian cell-based therapy type

Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group.

NewAmsterdam Pharma - Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating Obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy. In January 2021, NewAmsterdam completed its Series A funding round of $196M (€160M) which will support the full Phase 3 development of Obicetrapib.

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology). We have established deep roots throughout Europe, and more recently, expanded outside of Europe, with the creation of an affiliate in Canada. Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care. Nordic Pharma's values of Commitment, Ambition, Respect, Reliability, Integrity and Agility describe our culture and standards and guide us in our way of working.

Imagine a world where we conquer cancer and genetic diseases. At NTrans Technologies, we solve key challenges in cell and gene therapy: Delivering life-changing therapies to the right cells and tissues. We leverage nature's own mechanisms for cellular uptake to ensure efficient and safe therapeutic delivery. Welcome to the next frontier of medicine. Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy. We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies. The mission of NTrans Technologies is to become the leading non-viral delivery platform in cell and gene therapy. Please contact us at: info@ntranstechnologies.com

At Oncosence we target cancer by developing senescence inducing and senolytic (senescent cell killing) compounds

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

Orexa is a phase 2 pharmaceutical company that develops and commercializes therapeutics to increase food intake. Its lead compound ORE-001 is a proprietary oral formulation, based on a well known anesthetic. The company has started its first phase 2a study in the Prevention of Post-Operative Ileus. Furthermore it is in preparation for phase 2a studies in Anorexia and Cachexia. With these three indications increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings. Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands. Attractive risk/reward: • Lower risk, because the active substance is already well known for many decades; • Lean and fast development plan; • Very attractive market potential. Strong patent portfolio: • Broad claims for all local anesthetics to increase food intake after both single and repeated administration; • Well understood mode of action; • Novel mode of delivery, with a proprietary oral formulation. We are looking for partnerships with: ★ an experienced mid or big pharma company with a focus on 505(b)(2) applications for the late stage clinical development and for the marketing in the US & EU markets (and possibly more); ★ a suitable Chinese company with experience in phase 2 & phase 3 clinical trials and an effective sales channel in the majority of the Chinese market; ★ a large scale specialized animal food company or a large veterinary drug company for the veterinary applications. We’d love to hear from you. We’ll get back to you as soon as we can! You can contact us at info@orexa.nl.

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

Pantarhei Bioscience BV (PRB) is a company in The Netherlands with an innovative concept of drug development in Woman’s Health. PRB's wholly owned subsidiary company – Pantarhei Oncology (PRO) (http://www.pantarheioncology.nl) develops innovative treatments for Endocrine Cancer. PRB and PRO have developed a product pipeline based on the proven ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals and combinations thereof in these areas of medicine. The main areas of expertise of PRB are reproductive hormone related treatments such as contraception and menopausal hormone therapy (MHT). The main areas of expertise of PRO are and in oncology breast cancer, prostate cancer and ovarian cancer. The business concept of PRB and PRO is to develop the patented new treatment concepts up to proof-of-concept (PoC) in the human (phase II). Using existing molecules often provides first evidence of safety. The business model is based on solid patent protection, internal project management and external research and development activities. Intellectual property (IP) and data supporting the new treatment concepts are licensed out for completion of clinical development (phase III), regulatory approval and sales and marketing by a licensee/partner.

OUR NUTRIENT DRUG CONJUGATE TECHNOLOGY (NDCt)™ - turns parenteral compounds into oral variants or improves oral bioavailability. - uses specific transporter proteins for food, i.e. active transport over the gut wall. - delivers tailor made solutions with our toolbox of linkers and nutrient. PATIENTS BENEFITS: - Oral administration is by far the preferred route and GI side effects may diminish, both improving compliance and with that efficacy - Enhanced bioavailability gives less inter-patient variability - New indications for the same compound BENEFITS TO COMPANIES: - Life cycle management from an NCE (new IP, often COM). - Short route to approval. - NDCt platform broadly applicable, irrespective of disease area. - Accelerate development of pipeline products. - Once promising, but now shelved research, can be revived. NDCt GIVES CONTROL OVER THE COMPOUND We chemically attach a nutrient mimic via a linker to the drug. The linker has profound effects on transport and synthesis. The nutrient mimic is a transporter substrate – recognized by the intestinal wall – facilitating active transport (vs passive transport of old-fashioned drugs). Subsequent enzymatic cleavage in the bloodstream, liberating the drug. With our patented NDCt we address the full spectrum of issues around oral bioavailability and control the compound. PROVIDING THE MISSING LINK PharmaCytics developed a toolbox of proprietary linkers and nutrient mimics. With our bifunctional linker variants it is even possible to couple drugs to biomolecules, such as proteins and antibodies. In addition, our linker technology can produce mutual prodrugs (or codrugs) in which two different synergistic acting pharmacological agents are linked together. LET US REVIVE HIDDEN TREASURES IN YOUR PIPELINE PharmaCytics brings in its expertise on medicinal chemistry, prodrug technology and drug delivery to solve and improve on your drug development issues. CALL US AND CHALLENGE US!

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Phlox Therapeutics pioneers gene therapy to alleviate and cure cardiomyopathies. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short by leveraging RNA-based strategies to reduce the negative effects caused by genetic mutations.

Pleco Therapeutics is a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the cancer microenvironment. Their Plecoid™ therapies positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals.

We are ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases. We focus our drug development mainly on a group of blinding disorders affecting the retina, called inherited retinal diseases.

ProteoNic is a biotechnology company active in development and licensing of DNA technology for cell line generation and recombinant protein production for pharmaceutical applications. We offer premium vector technology that substantially boosts production levels of therapeutic proteins and other biologics. Cost savings are immediate and sizeable, freeing up production capacity and enabling commercially viable production of difficult to express proteins. ProteoNic's 2G UNic™ drives higher production for all types of therapeutic protein products, including monoclonal antibodies, biosimilars and more difficult-to-express (DTE) proteins, such as Fc-fusion proteins and bi-specifics, contributing to their economic viability. Our patented technology does not require modifications to existing production systems or work flows and is compatible with all production cell lines and expression systems used in the industry. Independent technical and commercial validation by third parties, including top tier biopharma, demonstrates severalfold productivity level increases that translate into multi-million Euros in annual cost savings. The technology has wide ranging potential to boost production efficiencies in other important applications, including viral vector production, protein production in yeast and technologies which impact product quality. The company is headquartered at the BioScience Park in Leiden, the Netherlands and has a Boston, USA office for Business Development in the North American market.

Sairopa develops novel treatments for cancer by modulating the patient’s immune system. Early 2021 Sairopa acquired, backed by a reputable biotech investor, a portfolio of therapeutic antibodies from an American public company. Sairopa will enter clinical testing of two of its lead compounds in Phase 1 clinical trials in 2022. The company is based in Rotterdam, the Netherlands but operates internationally & virtually. To advance our programs, we are looking for a project manager that wants to make a difference and has a pioneer’s mentality.

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication. Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.

The history of Self-screen is a track record in translational science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of cancer, thereby to the benefit of patients around the world. Currently, the company's main focus is on cervical cancer screening and prevention. The company has two clinically validated assays on the market. We strive towards all-molecular screening to ensure objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline currently focuses on the extension of our science towards other sample types, like urine, and towards other cancer types. HPV-Risk Assay The HPV-Risk Assay is an in vitro real-time PCR-based assay The HPV-Risk Assay is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA, targeting the E7 region of the following 15 (probably) high-risk HPV genotypes, i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67, and 68. The QIAsure Methylation Test The QIAsure Methylation Test is a real-time PCR-based molecular assay The QIAsure Methylation Test is a real-time PCR-based molecular assay to distinguish women with cervical (pre)cancer. The QIAsure Methylation Test specifically detects women with a cancer-like methylation profile that have a short term high risk for progression to cervical cancer.

SERDA Therapeutics is a biopharmaceutical company that develops a wound debridement solution specifically designed to treat severe burn injuries and persistent ulcers such as pressure ulcers.

Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.

Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.

Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation, and delivery of a wide range of complex and custom-designed assays. With a team of 150 across five global laboratory locations; Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA), we provide innovative solutions to support our customers to achieve their clinical milestones. Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies. We pride ourselves on our deep scientific expertise and our ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis. We partner with our customers to contribute to the furtherment of scientific development and ultimately better management and treatment of human health. Synexa, improving the quality of human health through innovative biomarker and bioanalytical solutions.

Syngle Therapeutics is focused on developing an immunotherapy for the treatment of Parkinson’s disease. Syngle possesses several antibodies against oligomeric alphasynuclein, the main toxic species in Parkinson pathology.

Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. We are headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.

TargED started in September 2018 and is currently developing one biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. TargED pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke.

A clinical-stage biotechnology company pioneering a female-focused precision medicine approach using validated biobanks for the discovery, development, and commercialization of novel therapeutics and companion diagnostics in women's health.

More specifically, Trajectum Pharma is developing novel mRNA-based products, formulated as lipid nanoparticles for the field of rheumatoid arthritis and other inflammatory diseases. Trajectum Pharma is developing a potentially curative, first in class treatment, for which initial proof-of-concept for the treatment of RA has been established.The initial results in preclinical disease models are extremely promising. The long-term vision of the company is to develop an off-the-shelf vaccine for RA, using the principle of tolerance induction. The company has strong ties with Utrecht University, Department of Immunology and Infectious Diseases, Faculty of Veterinary Medicine (Prof. Femke Broere). There is an ongoing co-operation in the field of mRNA technology and lipid nanoparticle formulations with the Weissman Lab at UPenn (Philadephia, PA) (Prof. Drew Weissman).

Treeway is a clinical-stage biotech company developing therapy for ALS, Alzheimer's Disease and other neurodegenerative diseases. Treeway has been formed by the words tree of life and pathway of a disease, for the founders the symbolic way towards a cure. We foresee that medication, research and care will change dramatically in the coming decades and patients will become an essential part of this process on their pursuit for cures in rare and common diseases. Everyone can make a difference and our slogan "one man can and will find a way, why not be that man?"​ underpins our drive.

Uneedle realises a proprietary microneedle platform "Bella-mu" and "Bella-Vue", co-developing intradermal & suprachoroidal administered medicinal products with pharmaceutical partners. Uneedle is the legal manufacturer of this superior - short lumen - delivery platform. The single, hollow "Uneedles" are FDA approved and CE marked for direct application in the clinics worldwide.

uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.

VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020. This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need. By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide. Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases. With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy. Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022. We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow. We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than 13,000 real-world implantations. As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.

Vico Therapeutics is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. Vico is initially targeting spinocerebellar ataxia types 3 and 1 and Huntington’s disease. Our VICOMER platform designs antisense oligonucleotides for various genetic defects by modulating or editing RNA.

ViroNovative BV, established in 2002, is dedicated to providing a complete solution to human Metapneumovirus (hMPV), a virus discovered in 2001 at the Department of Viroscience, Erasmus MC. To this end, ViroNovative is co-developing diagnostics, vaccines, antibodies and antivirals for the detection, prevention and treatment of hMPV infection. With a strong network of industrial partners (to date 20 licenses on the hMPV patents are active) we generate new products and economic value.